DANIEL WANG
Urology Physician in BRANDYWINE, Maryland. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
DANIEL WANG reported a CMS MIPS final score of 83.566/100 — above the 83.1 national average — and filed 409 Medicare Part D claims in 2023.
- 83.566/100
- MIPS score · +0 vs avg
- 409
- Part D claims, 2023
- 76%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
DANIEL WANG's MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure
84 42nd percentile higher than 42% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
DANIEL WANG practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 2 hospital affiliations — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about DANIEL WANG?
Near national averagePrimary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in Maryland
How Urology Physician compares to other specialties among Maryland providers
Urology Physician share within Maryland
Urology Physician is one of the more visible NUCC categories in Maryland
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Medicare quality performance — MIPS
DANIEL WANG's 2023 MIPS final score plotted against the Urology Physician national average
- MIPS Final Score
- 83.566/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Urology Physician) — 83.566/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Quality dim CMS Quality category
- Cost dim CMS Cost category
- Specialty volume Urology Physician US NPIs
83.566/100 MIPS final score — 0.5 pts above the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Urology Physician. Quality dim: 81.553. Cost dim: 71.1669.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
DANIEL WANG appears in the CMS NPPES registry as a Urology Physician provider at 7704 MATAPEAKE BUSINESS DR STE 310, BRANDYWINE, MD, 20613, with a listed phone of (301) 868-0202. NPI 1164956520 was issued on 04/12/2017. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what WANG most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 409 prescription claims written by this provider, covering 149 Medicare beneficiaries and totaling roughly $80K in drug spend, split 24% brand-name and 76% generic by claim count, with an opioid prescribing rate of 3.2%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 83.566/100 for the 2023 performance year (Quality 81.553, Cost 71.1669), compared with the national average of 83.1.
Urology Physician is a mid-sized specialty nationwide, with 13,350 enrolled providers across 54 states and an average of 1,280 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1164956520 |
|---|---|
| Specialty | Urology Physician |
| Gender | Male |
| NPI Issued | 04/12/2017 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm DANIEL WANG's current license status, disciplinary history, and board certifications with the Maryland Board of Physicians in Maryland before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Group practice
Hospital and facility affiliations
Facilities where DANIEL WANG bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Industry payments received (2024) — CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for DANIEL WANG. Source: openpaymentsdata.cms.gov.
Total received
$5.2K
Largest payer
Axonics, Inc.
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
Brand vs generic prescribing mix · Typical
24% brand-name claims vs 76% generic, on 409 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 719
- Total Day Supply
- 18,985
- Brand vs Generic
- 24% brand / 76% generic
- Brand Drug Cost
- $70K
- Generic Drug Cost
- $10K
- Opioid Claims
- 13 (3.2% rate)
- Antibiotic Claims
- 86
Patient Demographics
- Average Patient Age
- 71.3 years
- Avg HCC Risk Score
- 1.35
- Gender Split
- 33% female / 67% male
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What DANIEL WANG prescribes most
Top Medicare Part D drugs by claim count, 2023
- Tamsulosin Hcl
Tamsulosin Hcl
107 claims
- Myrbetriq
Myrbetriq
75 claims
- Ciprofloxacin Hcl
Ciprofloxacin Hcl
53 claims
- Oxybutynin Chlorid… 20
Oxybutynin Chloride Er
20 claims
- Trospium Chloride 20
Trospium Chloride
20 claims
- Finasteride 17
Finasteride
17 claims
- Gemtesa 17
Gemtesa
17 claims
- Sulfamethoxazole-T… 13
Sulfamethoxazole-Trimethoprim
13 claims
| Drug | Claims |
|---|---|
| Tamsulosin Hcl | 107 |
| Myrbetriq Mirabegron | 75 |
| Ciprofloxacin Hcl | 53 |
| Oxybutynin Chloride Er Oxybutynin Chloride | 20 |
| Trospium Chloride | 20 |
| Finasteride | 17 |
| Gemtesa Vibegron | 17 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 13 |
| Tolterodine Tartrate Er Tolterodine Tartrate | 13 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Urology Physician Overview
How DANIEL WANG fits within the Urology Physician landscape nationally.
DANIEL WANG's 409 claims are below the specialty average of 1,280.
Nearby Urology Physician Providers in Maryland
Other clinicians with the same primary specialty enrolled in Maryland, drawn from the same CMS NPPES roster as WANG.
Compare Urology Physician nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Maryland
Frequently Asked Questions
What is DANIEL WANG's specialty? ▼
How much does DANIEL WANG prescribe under Medicare Part D? ▼
What is DANIEL WANG's Medicare quality score? ▼
Where is DANIEL WANG located? ▼
What is DANIEL WANG's NPI number? ▼
Does DANIEL WANG prescribe more brand-name or generic drugs? ▼
Does DANIEL WANG prescribe opioids? ▼
How many Urology Physician providers are there in the US? ▼
What drugs does DANIEL WANG prescribe most often? ▼
Does DANIEL WANG accept Medicare? ▼
How can I verify DANIEL WANG's credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology